Medication info
Olmesartan Medoxomil/Amlodipine Besylate/Hydrochlorothiazide Tablets 5/20/12.5 milligrams

Olmesartan Medoxomil/Amlodipine Besylate/Hydrochlorothiazide Tablets 5/20/12.5 milligrams

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Medica Korea Co., Ltd.
Appearance
White-orange round film-coated tablet
Packaging
30 tablets/Alu-Alu[(10 tablets/Alu-Alu × 3)]
Approval status
Active

MFDS item code 202002972 · Approved 2020.04.24 · Insurance code 646005450

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
Take 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the doses of the individual components (amlodipine and olmesartan medoxomil, as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. Recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The strengths of the individual components are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg ၀ Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5mg once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal failure. This medicine must not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). ၀ Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine must not be administered to patients with severe hepatic impairment. ၀ Older adults (65 years and older) Treatment should generally be initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults. Because experience with this medicine in adults aged 75 years and older is very limited, monitor very carefully during administration.
Child dose
The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.

Ingredients

Manufacturer
Medica Korea Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
View approved original text

This medication is used in combination therapy of Amlodipine and Olmesartan Medoxomil for patients with essential hypertension whose blood pressure is not adequately controlled. It efficiently lowers blood pressure and reduces the risk of cardiovascular complications. It aids in hypertension management and reduces strain on the heart and blood vessels, improving overall health.

How to take

Adult dose

Take 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the doses of the individual components (amlodipine and olmesartan medoxomil, as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. Recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The strengths of the individual components are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg ၀ Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5mg once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal failure. This medicine must not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). ၀ Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine must not be administered to patients with severe hepatic impairment. ၀ Older adults (65 years and older) Treatment should generally be initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults. Because experience with this medicine in adults aged 75 years and older is very limited, monitor very carefully during administration.

Child dose

The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.

Precautions

This medication can cause serious harm or death to the fetus and newborn if used during the second and third trimesters of pregnancy, so treatment must be discontinued immediately upon confirmation of pregnancy. Patients with allergies to any ingredients or related drugs, those who are pregnant or breastfeeding, or those with severe hypotension, heart valve problems, unstable heart failure after acute myocardial infarction, or severe kidney or liver impairment should not take this medication. Patients with reduced blood volume or renal function may experience hypotension initially when starting this medication. Their condition should be closely monitored, and appropriate measures taken as needed. This medication may affect kidney function, so patients dependent on renal function, kidney transplant recipients, or those with renal artery stenosis should exercise caution when using it. Patients with impaired liver function or liver disease are at risk for hepatic coma, and this medication is not recommended for those with severe liver impairment. During treatment, blood pressure may drop too low, causing dizziness or orthostatic hypotension, so caution is advised with activities such as heights or driving. This medication can cause electrolyte imbalances, so electrolyte levels should be regularly monitored through blood tests. Particular caution is necessary when taking this medication with potassium supplements or potassium-sparing diuretics, as potassium levels may increase. Numerous drug interactions may occur; consult a physician or pharmacist if taking other medications. Efficacy and safety for children and adolescents under 18 years have not been established, so its use is not recommended. In older adults, dosage should be adjusted with consideration for reduced renal and liver function, and caution should be exercised during use. In case of overdose, symptoms such as hypotension, palpitations, and bradycardia may occur, necessitating immediate treatment and monitoring in a hospital. This medication should be stored away from moisture, heat, and direct sunlight in a place inaccessible to children. Skin photosensitivity reactions may occur during treatment, so care should be taken to avoid excessive sun exposure. Women who are pregnant or planning to become pregnant should consult a physician before taking this medication, and breastfeeding mothers should either avoid it or consult a specialist.

Side effects

Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, sensitivity to stimulation, anxiety, mood changes, sleep disorders, neurological abnormalities, orthostatic dizziness, syncope, taste disturbances, hypertonia, sensory decrease, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremors, visual disturbances, reduced tear production, worsening myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina pectoris, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, bloating, indigestion, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, vascular edema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like reaction, eruptive pustulosis, exfoliative dermatitis, hyperhidrosis, photoreaction, pruritus, purpura, angioedema, rash, recurrence of lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, increased urinary frequency, acute renal failure, hematuria, voiding dysfunction, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial edema, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated serum creatinine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, altered consciousness, drug hypersensitivity, epigastric pain, decreased libido, labial edema, asthenia, eczema, limb pain, slight decrease in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, epistaxis, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is important to keep the storage temperature between 1°C and 30°C to maintain the medication's effectiveness and safety over time.

Appearance and packaging

Appearance

White-orange round film-coated tablet

Package unit

30 tablets/Alu-Alu[(10 tablets/Alu-Alu × 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.